论文部分内容阅读
已知在抗癌药引起的呕吐刺激传导中与5-HT及其受体之-5-HT_3受体有密切关系,现正在开发以granicetolon为主的5-HT_3受体拮抗剂作为癌化疗时的制吐剂。抗癌药诱发恶心、呕吐的发病机理:全身投给抗癌药主要刺激存在于小肠粘膜的一种内
It is known that there is a close relationship between the 5-HT-3 receptor of 5-HT and its receptor in the anti-cancer drug-induced vomiting and the 5-HT 3 receptor antagonist currently being developed as a granicetolon Of the spit. Anticancer drug-induced nausea, vomiting pathogenesis: systemic administration of anti-cancer drugs mainly in the presence of a small intestinal mucosa